Actavis plc and its partner Perrigo Company plc have announced that Actavis has received US Food and Drug Administration approval for their abbreviated new drug application (ANDA) for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the US. The product will be packaged and marketed under store and proprietary brands and will be an alternative to Mucinex D tablets. Mucinex D (guaifenesin/pseudoephedrine tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $83 million through food, drug and mass merchandisers over the last 12 months, according to information from Actavis.

Source: Actavis